Comparative Pharmacology
Head-to-head clinical analysis: ABITREXATE versus ADRUCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABITREXATE versus ADRUCIL.
ABITREXATE vs ADRUCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate, the active ingredient, is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby blocking the conversion of dihydrofolate to tetrahydrofolate, inhibiting DNA synthesis, repair, and cellular replication. It also has immunosuppressive and anti-inflammatory effects via modulation of adenosine and cytokine pathways.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
7.5 mg orally once weekly; alternatively, 7.5 mg subcutaneously once weekly. Dose may be increased by 2.5 mg every 1-2 weeks up to 20 mg once weekly based on response and tolerability.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (mean 7.5 hours) in patients with normal renal function; prolonged in renal impairment.
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for <10%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Category C
Category C
Antimetabolite
Antimetabolite